Billing and reimbursement NAGLAZYME® (galsulfase) is indicated for patients with mucopolysaccharidosis VI (MPS VI). NAGLAZYME has been shown to improve walking and stair-climbing capacity. BPPS will provide information and support The BioMarin Patient and Physician Support program (BPPS) is staffed by patient advocates with a thorough knowledge of the treatment and reimbursement process Information about pricing, reimbursement, and cost modeling of NAGLAZYME is available through BPPS BPPS advocates provide individualized support to patients and treating physicians who are navigating the medical insurance coverage system For more information, contact BPPS at this toll-free number: 866-906-6100, or email BPPS: bpps@bmrn.com Reimbursement forms for download Patient authorization to share medical information Statement of medical necessity NAGLAZYME full prescribing information Benefits of treatment with NAGLAZYME NAGLAZYME, the first and only enzyme replacement therapy (ERT) for the treatment of MPS VI, is a valuable therapy for patients. NAGLAZYME is the first and only ERT for the treatment of the chronic, progressive, and debilitating disease MPS VI In clinical trials, NAGLAZYME has been shown to improve walking and stair-climbing ability NAGLAZYME has also been shown to dramatically reduce urinary GAG levels